Spots Global Cancer Trial Database for Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
Official Title: A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors
Study ID: NCT04249843
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory solid tumors
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cedars Sinai Medical Center, Beverly Hills, California, United States
Hematology Oncology Clinic, Baton Rouge, Louisiana, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
MD Anderson, Houston, Texas, United States
University of Virginia Comprehensive Cancer Centre, Charlottesville, Virginia, United States
Blacktown Hospital, Blacktown, New South Wales, Australia
The Kinghorn Cancer Centre, St Vincent Hospital Sydney, Sydney, New South Wales, Australia
One Clinical Research, Nedlands, Perth, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
